Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacology of Infectious Diseases
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1524272
This article is part of the Research Topic Natural Products and Nanotechnology: Next-Generation Therapies for Infectious Diseases View all 3 articles

Population Pharmacokinetics and Dosing Optimization of Imipenem in Chinese Elderly Patients

Provisionally accepted
  • Nanjing Drum Tower Hospital, Nanjing, China

The final, formatted version of the article will be published soon.

    Objectives: To assess the pharmacokinetics and pharmacodynamics of imipenem in a retrospective cohort of hospitalized Chinese older patients.Methods: A population pharmacokinetic (PPK) model was constructed utilizing a nonlinear mixed-effects modeling approach. The final model underwent evaluation through bootstrap resampling and visual predictive checks. Additionally, a population pharmacokinetic and pharmacodynamic analysis was conducted employing Monte Carlo simulations to investigate the impact of commonly used dosing regimens (0.25 g every 6 hours, 0.5 g every 6 hours, 0.5 g every 8 hours, 1 g every 6 hours, 1 g every 8 hours, and 1 g every 12 hours) on the likelihood of achieving the target therapeutic outcomes.Results: A total of 370 observations available from 142 patients were incorporated in the PPK model. A two-compartment PPK model with linear elimination best predicted the imipenem plasma concentrations, with the creatinine clearance as a significant covariate of clearance. Typical estimates for clearance, inter-compartmental clearance, central and peripheral volume were 13.1 L•h -1 , 11.9 L•h -1 ,11.7 L, 29.3 L, respectively.The pharmacokinetics of imipenem in elderly patients were effectively characterized by the established PPK model, which includes creatinine clearance as a key covariate. This research will enhance our understanding of imipenem elimination and support precision dosing in this patient demographic.

    Keywords: Imipenem, population pharmacokinetics, Dosing optimization, elderly patients, monte carlo

    Received: 07 Nov 2024; Accepted: 20 Dec 2024.

    Copyright: © 2024 Wang, Fang, Luo, Jin and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Huaijun Zhu, Nanjing Drum Tower Hospital, Nanjing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.